Back to Search Start Over

Patient preference between Cabazitaxel and Docetaxel for first-line chemotherapy in metastatic castrate-resistant prostate cancer (mCRPC): Results from the CABADOC randomized trial

Full Text Access
View/download PDF

Tools

Authors Abstract Subjects Details